No Data
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Good Position To Deliver On Growth Plans
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
MoonLake Obtains $500 Million Facility From Hercules Capital
MoonLake Immunotherapeutics Secures up to $500M in Non-dilutive Financing
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates